Market access and health economics
Market access landscape and strategy, real-world evidence and register-based analyses, health economic modelling, HTA and reimbursement applications, literature reviews, surveys and patient-reported outcomes.
BI & Analytics make it possible to make better, data-driven decisions.
Today’s world is full of data, but many struggle to translate them to knowledge and insights that support better decisions and action.
Our combination of business insight, a solid toolbox and communication skills brings you safely across the finish line.
We help DSB, Sund & Bælt, Novo Nordisk, Pfizer and many others.
Among other things, we are experts in:
We help our clients use internal and external data to answer the key questions below.
When the hottest trends right now are AI and machine learning, it is easy to believe that all analyses and decisions must be automated and cleansed of human input. That is not our approach.
We believe that the right analyses and tools can improve the quality of the decisions that need to be made. This is true no matter which of the four analysis questions is concerned.
Therefore, we take our departure in the decisions you need to make. We develop analyses and tools that enable you to make them better and faster.
We work for public authorities, private companies and interest groups. Some of these are competitors or have other types of conflicting interests.
For this reason, we only work for one client at a time within a specific field. We consider a project completed when the client has received and approved the final reporting and we have sent the last invoice. As soon as a project is completed, we can work for another authority/company/organisation in that field.
In certain subject areas, we have entered into a framework contract with an exclusive agreement. This means that in these fields, we do not work for anyone else.
In certain cases, when there is no risk of conflicting interests, we can – in full transparency – work for several clients simultaneously within the same field.
We have developed a model for Novo Nordisk that can extrapolate the development in diabetes in every city all over the world. The model gives each city the opportunity to extrapolate the prevalence and costs of diabetes. In this way, an overview of the challenge is created, and they become able to make fact-based decisions about possible solutions for their inhabitants. The tool is part of the project Cities Changing Diabetes.
Read more here.
We illustrated what has affected DSB’s journey numbers and income over the past five years. We identified internal and external drivers and calculated how each of them had affected the development in this period. The analysis helped DSB clarify which factors they needed to monitor to better understand the development in the train traffic.
Incentive helped The National Building Foundation (Landsbyggefonden) develop a generic, data-driven model for the economic potential of developing challenged housing areas.
We helped Novo Nordisk document the cost of different types of treatments within the obesity area. We did this by using large amounts of data from the expansive, unique Danish registers. Decisions about the use of anti-obesity medication can then be made on a factual and well-documented foundation.
We are always happy to have a non-committal chat, so please do not hesitate to contact us. We can set up a meeting at your office or online, or you can visit us in Holte or Odense.
Market access landscape and strategy, real-world evidence and register-based analyses, health economic modelling, HTA and reimbursement applications, literature reviews, surveys and patient-reported outcomes.
Cost analyses, business cases, investment analyses, pricing, fares, big data, public transport, regulation, market analyses.
Cost-benefit, cost-effectiveness, business cases, investment plans, climate plans, potential for improved effectiveness, regulation, taxes and expenses, projections and scenarios.
Cost-benefit, cost-effectiveness, internal interest, current value, tax distortion, effects on the state treasury, expenses, taxes.
Pricing excellence, value-based pricing, pricing of new products, design of new price models, optimising discounts and discount policy, price reviews.
Financial compensation calculations, mergers, state support, dominant positioning, intellectual property rights.
Analytics, BI, data, what if?, Python, Power BI, mapping, diagnosis, prognosis, recommendation, forecast, tools.